Unknown

Dataset Information

0

Phase IIb Study of Intranasal Glutathione in Parkinson's Disease.


ABSTRACT:

Background

Reduced glutathione (GSH) is an endogenously synthesized tripeptide depleted early in the course of Parkinson's disease (PD) and GSH augmentation has been proposed as a therapeutic strategy in PD.

Objective

This Phase IIb study was designed to evaluate whether a Phase III study of intranasal GSH, (in)GSH, for symptomatic relief is warranted and to determine the most appropriate trial design for a disease-modification study.

Methods

This was a double-blind, placebo-controlled trial of 45 individuals with Hoehn & Yahr Stage 1-3 PD. Participants were randomized to receive intranasal placebo (saline), 100 mg GSH, or 200 mg GSH thrice daily for three months, and were observed over a one-month washout period.

Results

All cohorts improved over the intervention period, including placebo. The high-dose group demonstrated improvement in total Unified PD Rating Scale (UPDRS) (-4.6 (4.7), P = 0.0025) and UPDRS motor subscore (-2.2 (3.8), P = 0.0485) over baseline, although neither treatment group was superior to placebo. One participant in the high-dose GSH cohort developed cardiomyopathy.

Conclusions

Although predicted improvements in PD total and motor scores were observed, these data do not suggest (in)GSH is superior to placebo after a three month intervention. The symptomatic effects are sufficient to warrant a delayed-start or wash-out design study for disease-modification trials. Whether long-term use of (in)GSH leads to clinical improvements that are sustained and significantly different than placebo will require appropriately-powered longer-duration studies in larger cohorts. The improvement in the placebo arm was more robust than has been observed in previous PD studies and warrants further investigation.

SUBMITTER: Mischley LK 

PROVIDER: S-EPMC5438472 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase IIb Study of Intranasal Glutathione in Parkinson's Disease.

Mischley Laurie K LK   Lau Richard C RC   Shankland Eric G EG   Wilbur Timothy K TK   Padowski Jeannie M JM  

Journal of Parkinson's disease 20170101 2


<h4>Background</h4>Reduced glutathione (GSH) is an endogenously synthesized tripeptide depleted early in the course of Parkinson's disease (PD) and GSH augmentation has been proposed as a therapeutic strategy in PD.<h4>Objective</h4>This Phase IIb study was designed to evaluate whether a Phase III study of intranasal GSH, (in)GSH, for symptomatic relief is warranted and to determine the most appropriate trial design for a disease-modification study.<h4>Methods</h4>This was a double-blind, placeb  ...[more]

Similar Datasets

| S-EPMC4609266 | biostudies-literature
| S-EPMC5516583 | biostudies-literature
| S-EPMC3736736 | biostudies-literature
| PRJNA75909 | ENA
| PRJEB57228 | ENA
| S-EPMC3651682 | biostudies-other
| S-EPMC8558863 | biostudies-literature
| S-EPMC4975823 | biostudies-literature
| S-EPMC9535587 | biostudies-literature
| S-EPMC10876781 | biostudies-literature